Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven J. O'Day, Paolo A. Ascierto, April K.S. Salama, Kim A. Margolin, Carmen Loquai, Thomas K. Eigentler, Tara C. Gangadhar, Matteo S. CarlinoSanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M. Kirkwood, Jedd D. Wolchok, Alexander Eggermont, Xiaoyun Nicole Li, Wei Zhou, Adriane M. Zernhelt, Joy Lis, Scot Ebbinghaus, S. Peter Kang, Adil Daud

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences